Haplotype Labs Analysis: $500K Raised
What is Haplotype Labs?
Haplotype Labs was founded in 2024 to improve human healthspan through population genetics software. The company builds SaaS tools and a community around polygenic risk models. Its stated goal is to reduce sequencing costs by 50% to 90% while eliminating bespoke pipelines.
Location
San Francisco, United States
Employees
1-10
Founded
2024
Investors
- Brainstorm Ventures
- Soma Capital
- Y Combinator
Product Features & Capabilities
- reduce sequencing costs by 50% - 90%, predict, detect, and prevent disease using polygenic risk models, streamline processes by eliminating bespoke software pipelines
How much Haplotype Labs raised
1 - $500,000
February 27, 2024Lead Investor: Saturnin Pugnet, Y Combinator
Who are the founders of Haplotype Labs
MP
Mike Polcari
Founder
Market Focus
Haplotype Labs primarily focuses on the biotechnology industry, specifically in the areas of genetic sequencing, disease prediction, and prevention through polygenic risk models, utilizing SaaS technology to enhance efficiency and reduce costs.
Business Model
SaaS platform generating revenue through subscriptions and partnerships with healthcare providers.
Competitors Overview
Haplotype Labs operates in the genomic SaaS market, focusing on reducing sequencing costs and predicting diseases through polygenic risk models. Its main competitors include:
-
Strand Life Sciences: This company offers genomic data analysis and interpretation services, focusing on personalized medicine. They have a strong emphasis on clinical applications and partnerships with healthcare providers, which may provide them with a competitive edge in clinical settings.
-
Concert Genetics: Specializing in genetic testing solutions, Concert Genetics provides a comprehensive platform for managing genetic testing data. Their advantage lies in their extensive network and partnerships with laboratories, which enhances their service offerings.
-
Beijing Zhongyin Technology: This company focuses on genetic testing and analysis, particularly in the Chinese market. Their local expertise and established presence in Asia may give them an advantage in regional markets.
These competitors differ in their specific focus areas, partnerships, and market strategies, which can influence their effectiveness in the genomic SaaS landscape.
See something that needs updating? Suggest edits to this profile.